IL17A and psoriasis: Taken together, our findings suggest that the dNP2-ctCTLA-4 peptide holds promise as a novel therapeutic approach for psoriasis, offering the potential to modulate immune responses, suppress inflammation, and mitigate the pathogenic effects associated with controlling IL-17A producing Th17, Tc17, and γδ T cells via increasing Treg cells.